ArticleFrontiers in microbiology2024
Nipah virus survey in
Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Nipah virus threat in India: Epidemiological trends, risk drivers, and lessons for pandemic preparedness.PLoS pathogens · 2026Review
- Re-emergence of Nipah Virus in Eastern India: Urgent need for enhanced surveillance.New microbes and new infections · 2026Article
- Nipah and chandipura viruses: Emerging neurotropic zoonotic viruses in south asia - a comparative review.Molecular biology reports · 2026Review
- Nepal's vulnerability to Nipah virus transmission: an urgent call for preparedness.Sustainable microbiology · 2026Article
- A One Health approach to understanding and managing Nipah virus outbreaks.Nature microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: India has experienced seven outbreaks of the Nipah virus (NiV) since 2001, primarily occurring in the southern and eastern regions of the country. The southern region has been the main site for these outbreaks. In contrast, the eastern region, which borders Bangladesh, has not reported any outbreaks since 2007. However, Bangladesh continues to experience nearly annual outbreaks, indicating a significant lack of surveillance in that area. To improve the country's preparedness and to gather support for enhancing public health surveillance in eastern and northeastern states near the area affected by the NiV, a cross-sectional survey was conducted to determine the prevalence of NiV in the bat species Methods: Throat and rectal swabs, blood samples, and organ samples were collected. Real-time quantitative reverse transcription PCR (qRT-PCR) was utilized for the detection of Nipah viral RNA, and sequencing was conducted for further confirmation. Bat IgG enzyme-linked immunosorbent assay (ELISA) was employed for antibody detection. Results: Throat and rectal swab samples of 212 Discussion: The serological and virological evidence obtained from the study indicates that a broader geographical area is under threat of spillover in India. It's crucial to implement a One Health approach connecting bat surveillance studies with human surveillance and risk factor studies in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.